Cretostimogene Shows Promising Results in Bladder Cancer Treatment
A new study presents promising results for cretostimogene grenadenorepvec, an investigational non–muscle invasive bladder cancer (NMIBC) agent. According to Mark D. Tyson II, MD, MPH, a urologic oncologist at the Mayo Clinic, treatment with cretostimogene in patients with high-risk, BCG-unresponsive NMIBC yielded a complete response rate of 75.5%. The study’s primary end point was complete … Read more